Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Zirabev (bevacizumab-bvzr)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

VEGF-A inhibitor

Related drugs:

‹

Cizumab (bevacizumab biosimilar) (0)

Equidacent (bevacizumab biosimilar) (0)

GB222 (bevacizumab biosimilar) (0)

HLX-04 (bevacizumab biosimilar) (0)

ranibizumab (0)

Onbevzi (bevacizumab biosimilar) (0)

Pusintin (bevacizumab biosimilar) (0)

TRS003 (bevacizumab biosimilar) (0)

HD204 (bevacizumab biosimilar) (0)

bevacizumab biosimilar (0)

hVEGF26–104/RFASE (0)

bevacizumab (416)

Aybintio (bevacizumab biosimilar) (14)

bevacizumab-maly (12)

bevacizumab-awwb (11)

bevacizumab-adcd (11)

bevacizumab-tnjn (8)

aflibercept intravitreal (7)

Krabeva (bevacizumab biosimilar) (7)

Byvasda (bevacizumab biosimilar) (4)

ziv-aflibercept IV (4)

SIBP-04 (bevacizumab biosimilar) (1)

BP102 (bevacizumab biosimilar) (0)

SCT510 (bevacizumab biosimilar) (0)

Ankada (bevacizumab biosimilar) (0)

BI 695502 (bevacizumab biosimilar) (0)

MIL 60 (bevacizumab biosimilar) (0)

LY01008 (bevacizumab biosimilar) (0)

CBT124 (bevacizumab biosimilar) (0)

Cizumab (bevacizumab biosimilar) (0)

Equidacent (bevacizumab biosimilar) (0)

GB222 (bevacizumab biosimilar) (0)

HLX-04 (bevacizumab biosimilar) (0)

ranibizumab (0)

Onbevzi (bevacizumab biosimilar) (0)

Pusintin (bevacizumab biosimilar) (0)

TRS003 (bevacizumab biosimilar) (0)

HD204 (bevacizumab biosimilar) (0)

bevacizumab biosimilar (0)

hVEGF26–104/RFASE (0)

›

No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	bevacizumab-bvzr Resistant: A1 - Approval bevacizumab-bvzr Resistant : A1	bevacizumab-bvzr Resistant: A1 - Approval bevacizumab-bvzr Resistant : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1